Stay updated with breaking news from லோரெம் அடித்தளம். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Empowering the Fight Against Rare Diseases One Disease at A Time clinicalomics.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from clinicalomics.com Daily Mail and Mail on Sunday newspapers.
n-Lorem Foundation Forms Partnership with Manufacturer Oligonucleotide Nitto Avecia globalgenes.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globalgenes.org Daily Mail and Mail on Sunday newspapers.
Ionis Pharmaceuticals (IONS) Names Joseph Loscalzo Chairman, Allene Diaz Appointed Director streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Published: May 21, 2021 By Alex Keown Biopharma and life sciences companies strengthen their leadership teams and board with these Movers & Shakers. AavantiBio – Jessie Hanrahan was named chief regulatory officer of AavantiBio. Hanrahan will oversee global regulatory affairs for AavantiBio’s diversified pipeline of gene therapy programs targeting rare diseases with significant unmet medical needs. Most recently, she was Vice President of Regulatory Science at bluebird bio, Inc. Prior to bluebird bio, Hanrahan held positions of increasing responsibility at Genzyme Corp. where she worked across the oncology, multiple sclerosis and rare disease therapeutic areas. Earlier in her career, Hanrahan worked at Boston Scientific Corporation. ....
Share Rare Daily Staff n-Lorem Foundation, a nonprofit that provides free, lifetime supplies of individualized RNA-targeted medicines to patients living with ultra-rare diseases, said it entered into a partnership with Ultragenyx Pharmaceutical to bolster n-Lorem’s efforts. Ultragenyx joins Ionis Pharmaceuticals, Biogen, Charles River Labs, Covance by Labcorp, and Korea Institute of Toxicology as industry partners supporting n-Lorem’s work. Ultragenyx focuses on developing products for serious rare and ultra-rare genetic diseases, and the company’s President and CEO Emil Kakkis brings a wealth of expertise through his work on policy and industry issues affecting rare disease treatment development. The additional resources, financial contribution, and experience from both the company and Kakkis will be critical as n-Lorem continues to scale-up its unique charitable treatment model to help patients with ultra-rare mutations, the foundation said. ....